Shake-up at Valeant signals stunning fall from grace for J Michael Pearson
Pharmaceutical giant faces a growing list of questions from investors and regulators
Investors and directors discover it’s good to talk
The Bottom Line: a little communication with shareholders would go a long way
Valeant’s unsolicited bid for Allergan part of a cheeky business model
Valeant Pharmaceuticals is a drug company that doesn’t develop drugs – it runs a serial takeover operation
Bid for Botox maker injects more life into growing merger trend among drugmakers
Canadian pharma firm teams up with Wall Street hedge fund mogul to mount hostile takeover of Allergan
YOU MAY ALSO LIKE...
Crosswords & Puzzles
Crosswords & puzzles to keep you challenged and entertained
Stardust
Inquests into the nightclub fire that led to the deaths of 48 people
Common Ground
How does a post-Brexit world shape the identity and relationship of these islands
Family NoticesOpens in new window
Weddings, Births, Deaths and other family notices